Quick Facts

• Condition Treated: Replacement therapy for adult males with testosterone deficiency
• Specific Uses: Primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired)

---

Striant (testosterone) is authorized as replacement therapy in adult males for conditions resulting from an absence or deficiency of natural testosterone. The main use of this medication is to treat male hypogonadism.

Primary Uses and Benefits

The buccal system is indicated for two categories of hypogonadism: Primary hypogonadism and hypogonadotropic hypogonadism. Primary hypogonadism is caused by testicular failure due to congenital or acquired factors, such as conditions like Klinefelter's syndrome or following orchiectomy. Hypogonadotropic hypogonadism is caused by deficiencies or injuries related to the pituitary gland or hypothalamus.

The therapy works to restore serum testosterone concentrations to a typical physiological range. Benefits of replacement therapy in men with confirmed hypogonadism may include the maintenance of secondary sexual characteristics, improvement of sexual function and libido, and potential increases in bone density and muscle mass.

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed	Adult Males with confirmed Primary Hypogonadism or Hypogonadotropic Hypogonadism.
Populations for whom use is contraindicated	Women (including those who are or may become pregnant, or are breastfeeding). Men with Carcinoma of the Breast or known or suspected Carcinoma of the Prostate.
Age-related eligibility rules	Males less than 18 years old: Safety and efficacy have not been established. Geriatric Patients: Insufficient long-term safety data to fully assess potential risks.
Condition-specific eligibility rules	Use requires caution in patients with pre-existing cardiac, renal, or hepatic disease due to the risk of edema. BPH patients must be monitored closely for worsening symptoms.

---

Resulting Eligibility Structure

Official regulatory documents define the eligible population as adult men with specific forms of documented low testosterone. Absolute contraindications prohibit use by women and by any man with carcinoma of the breast or known/suspected carcinoma of the prostate. Use is generally not established for males under 18 or for men with age-related hypogonadism. Furthermore, conditional use limitations require close patient monitoring for those with pre-existing organ disease or Benign Prostatic Hyperplasia (BPH).

Interactions with other medicines and products

This section summarizes interactions with other medicinal products and non-medicinal substances as documented in official government regulatory information.

Interaction Scope

Entity Type	Documented Interactions
Medicinal Product Categories	Oral Anticoagulants, Corticosteroids, Insulin and/or other Antidiabetic Agents.
Specific Interacting Medicines	Warfarin (as an example of an Oral Anticoagulant).
Mechanistic Basis of Interactions	Testosterone may increase sensitivity to oral anticoagulants. Concomitant use with corticosteroids may result in increased fluid retention. Concomitant use with Insulin/Antidiabetic Agents may decrease blood glucose and insulin requirements.
Population-Specific Notes	Increased fluid retention risk with corticosteroids is noted for caution, particularly in patients with cardiac, renal, or hepatic disease.
Interaction-Related Restrictions	Frequent monitoring of International Normalized Ratio (INR) and prothrombin time is recommended in patients taking oral anticoagulants.

Official Interaction Statements

• Concomitant use with oral anticoagulants (e.g., warfarin) may increase the risk of bleeding; frequent monitoring of coagulation parameters is required.
• Co-administration with corticosteroids may lead to fluid retention.
• For patients with diabetes, co-administration with testosterone may decrease blood glucose and insulin requirements, necessitating adjustment.

Connection to the Overall Interaction Profile

Official regulatory documents define the product's interaction profile by identifying agents that necessitate intensive clinical monitoring (coagulation tests with anticoagulants) or carry a cautionary risk for specific adverse outcomes (fluid retention with corticosteroids). The profile also includes a procedural constraint on managing blood glucose control when co-administered with antidiabetic agents. These statements strictly mandate awareness of required adjustments and monitoring without detailing mechanisms or therapeutic context.

How Striant (Testosterone) Works

---

Direct Ligand Binding and Genomic Modulation

The mechanism begins with testosterone acting as an agonist by binding to the intracellular Androgen Receptor (AR), a nuclear transcription factor. This activated complex then translocates to the nucleus to modulate gene expression, initiating or suppressing the production of specific proteins. This genomic action engages pathways that increase protein synthesis and modulate cellular processes essential for muscle mass and the structure of the bone matrix.

---

Enzymatic Conversion and Dual-Pathway Signaling

The physiological effects of testosterone include those mediated by its role as a precursor, being enzymatically converted into two key metabolites: Dihydrotestosterone (DHT) via 5alpha-Reductase and Estradiol (E2) via Aromatase. This Dual-Pathway Signaling allows the active ingredient to influence both androgenic and estrogenic receptor systems. The resulting E2 action influences pathways involved in bone resorption and bone formation, and modulates functions within the Central Nervous System (CNS).

---

Systemic Regulation via Negative Feedback

The presence of the replacement hormone immediately engages the Hypothalamic-Pituitary-Gonadal (HPG) axis through a sensitive negative feedback loop. This mechanism modulates systemic endocrine balance by resulting in the suppression of the pituitary hormones LH and FSH. This central feedback mechanism establishes the new systemic endocrine environment and simultaneously leads to the inhibition of the body's native testosterone production.

The Striant mucoadhesive buccal system is designed for transbuccal administration only, applied to the gum region for the continuous delivery of testosterone. The medication is supplied as a fixed-dose 30 mg buccal system, which represents the standard regimen for replacement therapy without a standard upward titration schedule.

Official Dosing and Frequency

The approved dosage regimen requires the application of one buccal system (30 mg) twice daily, spaced approximately 12 hours apart, typically administered in the morning and evening. The system is designed to adhere to the gum for the full 12-hour dosing interval until it is intentionally removed.

Procedural Administration and Special Conditions

For proper administration, the system is placed with the rounded side against the gum, just above the incisor tooth, and held firmly in place for 30 seconds to ensure initial adhesion. With each new application, the buccal system must be rotated to alternate sides of the mouth. It is directed that the system be removed prior to routine morning and evening oral care (e.g., brushing), and a new system immediately applied thereafter. The system must not be chewed or swallowed.

If the system is dislodged before the next scheduled dose, established protocols specify replacing it immediately with a new system and adjusting the timing of the next scheduled dose based on the elapsed time since the original application.

Use Limitations and Monitoring

The safety and efficacy of this specific buccal system have not been established in males less than 18 years old. Furthermore, therapy requires long-term monitoring; serum testosterone concentrations should be measured 4 to 12 weeks after initiation and periodically thereafter. Therapy is instructed to be discontinued if serum testosterone concentrations are consistently outside the normal physiological range (300 to 1050 ng/dL) despite correct use.

Research evidence / Overview of studies for Striant (Testosterone)

---

Evidence for use in Male Hypogonadism

Clinical trials have been used in research exploring the buccal system as a replacement therapy for men who have been diagnosed with a confirmed testosterone deficiency, a condition known as hypogonadism. This research has examined adult men with both primary hypogonadism (testicular failure) and hypogonadotropic hypogonadism (issues with the brain's hormone control system). The main outcomes related to systemic or functional imbalance that were monitored in these pivotal studies were pharmacokinetic measurements. This means that researchers primarily studied how well the medicine delivered the active ingredient into the bloodstream.

Studies monitored patients over relatively short-term intervals, typically lasting up to 12 weeks for the main assessments. The research highlighted changes measured during the study period related to the amount of testosterone circulating in the blood. Specifically, findings describe patterns observed in the studies where the medicine was associated with achieving and maintaining total serum testosterone concentrations within the established clinical physiological reference range, which is the primary biomarker outcome required for regulatory authorization.

---

Pharmacokinetic Studies and Delivery Profile

Research explored the absorption characteristics of the buccal delivery route by examining the resulting testosterone concentrations that were observed in the blood. Studies monitored the maximum concentration achieved in the blood, as well as the average concentration maintained throughout the day. Findings indicate that the mucoadhesive nature of the system was associated with observed patterns of sustained hormone release.

---

Long-Term Studies and Follow-up Data

While initial efficacy and safety were assessed in short-term trials, long-term effects are not fully established based only on those initial studies. To gather more information, patients who participated in the original trials were sometimes observed in open-label extension studies for up to two years.

---

What is Still Uncertain about the Research Landscape

The evidence base for the buccal system, like most research, still has certain gaps and limitations. Sample sizes were modest in some of the comparison studies against other testosterone formulations, and comparative evidence is lacking in large-scale, head-to-head randomized trials over long periods.

Regulatory sources note that research has not established the evidence base for use in two specific scenarios: males under 18 years old and men who experience age-related decline in testosterone levels (sometimes called late-onset hypogonadism) without a confirmed pituitary or testicular cause. Furthermore, follow-up durations were limited in the pivotal efficacy trials, which were often focused more on the biomarker outcome than on long-term clinical outcomes.

Key Studies & References

1. New Testosterone Buccal System (Striant) Delivers Physiological Testosterone Levels: Pharmacokinetics Study in Hypogonadal Men (Wang et al., 2004)
2. The longterm efficacy and safety of a testosterone mucoadhesive buccal tablet in testosterone-deficient men (Rhoden et al., 2013, reporting long-term data)

Common questions about Striant (Testosterone) (FAQ)

Q: What is Striant (Testosterone) used for?

A: Striant is a formulation of testosterone replacement therapy. It is used to treat men with conditions associated with a lack of, or low, natural testosterone in the body, which is often referred to as hypogonadism.

Q: How does the buccal system work?

A: The Striant system is a buccal tablet designed to be applied to the gum area, above the incisor tooth. This delivery method allows testosterone to be absorbed directly through the mucous membrane in the mouth into the bloodstream.

Q: What common side effects are associated with Striant?

A: Commonly reported adverse events during clinical trials included headache, gum or mouth irritation, gum pain, and taste disturbances. It is important to discuss potential side effects with a healthcare provider.

Q: Can Striant be used for bodybuilding or athletic enhancement?

A: Testosterone is a controlled substance. Its use is not approved for improving athletic performance, increasing muscle mass, or treating non-deficiency-related conditions. Use for these purposes may carry significant health risks.

Striant (testosterone buccal system) must be stored and handled according to specific regulatory requirements to maintain product integrity and ensure public safety.

Storage & Disposal Scope	Official Requirement
Temperature Requirements	Store at controlled room temperature: 20^circ to 25 C (68^circ to 77 F).
Environmental Protection	Keep away from excess heat and moisture; do not freeze; do not store in the bathroom.
Packaging Rules	Keep the system in its original closed container and intact blister card until the time of use.
Child-Safety Storage	Store the medication in a safe, locked location that is out of the sight and reach of children and pets.
Disposal Instructions	Used systems must be safely discarded in household trash in a manner that prevents accidental ingestion.
Environmental Disposal	Consult local regulations or a healthcare professional for disposal instructions; do not flush unused medicine unless instructed to do so.

The official labeling stipulates that used buccal systems should be immediately discarded into inaccessible household trash to prevent exposure to children and pets. This is consistent with the requirement that the controlled substance must be stored in a safe, locked location. Storage must strictly adhere to the designated room temperature range and protection from heat and moisture to preserve the product's stability.